Diabetic Macular Edema Market expected to grow at a steady CAGR during 2025-2033 | Top Companies - Novartis, Regeneron, Roche, Bayer, AbbVie | Exclusive report by DataM Intelligence

Leander, Texas and Tokyo, Japan - Jan.07.2026
As per DataM Intelligence research insights, the Diabetic Macular Edema market was valued at US$ 4.91 billion in 2024 and is projected to reach US$ 7.44 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2025-2033.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/diabetic-macular-edema-market?praveen

United States: Recent Industry Developments
✅ In December 2025, U.S. biopharmaceutical companies progressed innovative DME therapies, including sustained-release implants and combination treatments to enhance efficacy and patient adherence.

✅ In November 2025, retina specialists increased adoption of tele-ophthalmology and remote retinal screening programs, improving access to DME diagnosis and follow-up care.

✅ In October 2025, U.S. research institutions evaluated novel gene and cell-based approaches aimed at long-term management of diabetic macular edema.

✅ In September 2025, healthcare providers integrated real-world evidence and digital health tools into DME treatment strategies, supporting outcome-based care and personalized ophthalmology solutions.

Japan: Recent Industry Developments
✅ In December 2025, Japanese pharmaceutical companies advanced next-generation anti-VEGF and corticosteroid therapies for diabetic macular edema, focusing on longer dosing intervals and improved visual outcomes.

✅ In November 2025, ophthalmology clinics adopted AI-enabled retinal imaging and screening tools to support early detection and personalized treatment planning for DME patients.

✅ In October 2025, collaborations between medical device firms and hospitals expanded use of optical coherence tomography (OCT)-guided treatment protocols, improving monitoring of disease progression.

✅ In September 2025, national health initiatives promoted diabetes-related eye disease awareness programs, encouraging regular eye exams and early intervention for diabetic patients.

Diabetic Macular Edema Market: Drivers
- The market is growing due to the rising prevalence of diabetes and associated vision complications worldwide. Increasing awareness and early screening programs are driving demand for timely diagnosis and treatment. Advancements in anti-VEGF therapies, corticosteroid implants, and imaging technologies improve treatment outcomes and patient compliance. Expanding access to ophthalmology care, supportive reimbursement policies, and ongoing R&D in retinal therapies support sustained market growth.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/diabetic-macular-edema-market?praveen

Diabetic Macular Edema Market: Major Players
Novartis | Regeneron | Roche | Bayer | AbbVie | Samsung Bioepis | Kodiak Sciences | Oculis

Market Segmentation Analysis - Diabetic Macular Edema
By Type
Center-involved diabetic macular edema (CI-DME) dominates with approximately 65% share, driven by higher diagnosis rates and greater visual impairment risk requiring active treatment. Non-center-involved DME accounts for around 35%, often managed with monitoring, laser therapy, or adjunct treatments depending on disease progression.

By Treatment Type
Anti-VEGF therapy leads with nearly 55% share, supported by strong clinical efficacy, improved visual outcomes, and widespread adoption as first-line treatment. Corticosteroids account for approximately 25%, used particularly in patients with inadequate response to anti-VEGF therapy or with contraindications. Laser photocoagulation holds about 15%, primarily applied in non-center-involved cases and combination therapy approaches. Other treatments represent roughly 5%, including emerging therapies and combination regimens under clinical evaluation.

By Form
Injectable formulations dominate with around 80% share, reflecting the standard of care involving intravitreal injections for targeted drug delivery to the retina. Implant-based drug delivery systems account for nearly 15%, offering sustained-release benefits and reduced injection frequency. Other forms contribute approximately 5%, including investigational topical and oral formulations under development.

Regional Analysis - Diabetic Macular Edema Market
North America - 39% Share
North America leads with 39% share, driven by high prevalence of diabetes, advanced ophthalmic care infrastructure, widespread screening programs, and strong adoption of anti-VEGF and corticosteroid therapies in the U.S. and Canada.

Europe - 28% Share
Europe holds 28% share, supported by increasing diabetic population, strong reimbursement frameworks, and well-established eye care services across Germany, the U.K., France, Italy, and Spain.

Asia-Pacific - 22% Share
Asia-Pacific accounts for 22% share, fueled by rapidly rising diabetes prevalence, improving access to retinal diagnostics, and expanding adoption of advanced treatments in China, India, Japan, and South Korea.

South America - 6% Share
South America represents 6% share, driven by growing awareness of diabetic eye diseases, improving ophthalmology services, and increasing treatment access in Brazil, Mexico, and Argentina.

Middle East & Africa - 5% Share
Middle East & Africa account for 5% share, supported by rising diabetes incidence, gradual expansion of ophthalmic care infrastructure, and increasing screening initiatives in the UAE, Saudi Arabia, and South Africa.

Purchase this Report :
https://www.datamintelligence.com/buy-now-page?report=diabetic-macular-edema-market?praveen

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praveen

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.